Rakesh K. Jain

TL;DR: In vitro calibration and in vivo application of fluorescence ratio imaging to measure pH gradients in a biologically useful pH range are presented and FRIM should permit noninvasive in vivo evaluation of new pH-modifying agents and, in combination with other optical techniques, should offer novel mechanistic information about tumor pathophysiology.

TL;DR: The data suggest that LYVE‐1 and CD44 are not required for the formation or function of lymphatics, but do not rule out a role for LYve‐1 in inflammation.

TL;DR: The authors performed a phase 2 and biomarker study to evaluate trebananib, an angiopoietin 1 and angiopOietin 2 blocking peptibody, with and without bevacizumab in patients with recurrent glioblastoma.

TL;DR: The potential of RAS inhibitors to mitigate cancer treatment–related adverse events, with a special emphasis on chemotherapy-induced cardiotoxicity, radiation injury, and arterial hypertension is summarized.